

REMARKS/ARGUMENTS

The Final Office Action dated October 7, 2003 has been carefully reviewed, and these remarks respond to that Office Action. Applicants respectfully request entry of this Amendment, reconsideration of this application, as amended, and allowance of the application.

I. General Remarks Regarding The Content Of This Amendment

Claims 1-53 and 64-73 are canceled without prejudice or disclaimer by this Amendment, and new claims 74-119 take their place. New claims 74-119 are based on the previously presented claims, but the new claims are in a form suggested by the Examiner in Paragraph 13 of the Final Office Action. Specifically, support for new claims 74-119 may be found in the previous claims as described in the following table:

Previous Claims	New Claims
1-3	74
4	75
64-65	76-77, respectively
5-6	78-79, respectively
19-20	80-81, respectively
21-23	82
24	83
68-69	84-85, respectively
25-26	86-87, respectively
39-44	88-93, respectively
1, 7, 8	94
9-18	95-104, respectively
21, 27, 28	105
29-38	106-115, respectively
41-44	116-119, respectively

Accordingly, no new matter is included in this Amendment, and no additional claim fees are due as a result of this Amendment. Additionally, this Amendment does not raise any new issues that would require further searching or consideration by the Examiner. Entry and consideration of this Amendment are respectfully requested.

II. The 35 U.S.C. § 112, First Paragraph Rejection Is Moot

Claims 1-14, 21-34, 41-53 and 64-73 were rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking enablement. While Applicants do not agree with and respectfully traverse this rejection, *e.g.*, for the reasons set forth in the Amendment filed July 17, 2003, in order to expedite prosecution and to facilitate allowance of this application, Applicants have presented new claims drafted in the manner described by the Examiner in Paragraph 13 of the Final Office Action. Applicants appreciate the Examiner's comments and efforts to advance prosecution of this patent application. Withdrawal of this rejection and allowance of new claims 74-119 are earnestly solicited.

Applicants' decision to present new claims by this Amendment should not be construed as an admission that Applicants agree with or acquiesce in any of the Office's previous rejections. Rather, the new claims are presented only to expedite prosecution and to facilitate allowance of this present application. Applicants reserve all rights to pursue claims of the same or similar scope to any of the canceled claims, *e.g.*, in a continuing application.

III. Conclusion


By this Amendment, Applicants have amended the claims in this application into a form that the Examiner indicated would likely bring favorable consideration. Because the claims have

LISTING OF CLAIMS


This Listing of Claims will replace all prior versions and Listings of Claims in the application:

1 - 73. Canceled without prejudice or disclaimer.

74. (New) A support for oligonucleotide synthesis comprising: a support material represented by the following formula:



wherein substituent A is the following substituent:



wherein lcaaCPG and its accompanying substituent groups represent a long chain alkylamino controlled pore glass base material;

wherein substituent B is a member selected from the group consisting of an acyl group and an aroyl group; and

wherein substituent C is a member selected from the group consisting of a dimethoxytrityl group and a protecting group removable under acidic or neutral conditions.

75. (New) A support according to claim 74, wherein substituent B is an acyl group.


76. (New) A support according to claim 75, wherein the acyl group is selected from the group consisting of a chloroacetyl group, a dichloroacetyl group, a 4-chlorophenoxyacetyl group, and a 2,4-dichlorophenoxyacetyl group.

77. (New) A support according to claim 75, wherein the acyl group is a dichloroacetyl group.

78. (New) A support according to claim 74, wherein substituent B is a 4-chlorophenoxyacetyl group.


79. (New) A support according to claim 74, wherein substituent B is a 2,4-dichlorophenoxyacetyl group.

80. (New) A support according to claim 74, wherein the support material is




wherein DMTr represents a dimethoxytrityl group.

81. (New) A support according to claim 74, wherein the support material is




wherein DMTr represents a dimethoxytrityl group.

82. (New) An article represented by the following formula:



wherein substituent A is the following substituent:



wherein lcaaCPG and its accompanying substituent groups represent a long chain alkylamino controlled pore glass base material;

wherein substituent B is a member selected from the group consisting of an acyl group and an aroyl group; and

wherein substituent C is a member selected from the group consisting of a dimethoxytrityl group, a nucleotide-containing group, and a protecting group removable under acidic or neutral conditions.

83. (New) An article according to claim 82, wherein substituent B is an acyl group.


84. (New) An article according to claim 83, wherein the acyl group is selected from the group consisting of a chloroacetyl group, a dichloroacetyl group, a 4-chlorophenoxyacetyl group, and a 2,4-dichlorophenoxyacetyl group.

85. (New) An article according to claim 83, wherein the acyl group is a dichloroacetyl group.


86. (New) An article according to claim 82, wherein substituent B is a 4-chlorophenoxyacetyl group.

87. (New) An article according to claim 82, wherein substituent B is a 2,4-dichlorophenoxyacetyl group.

88. (New) An article according to claim 82 represented by the following formula:



89. (New) An article according to claim 82 represented by the following formula:




90. (New) An article according to claim 82, wherein substituent C is a nucleotide-containing group including at least one nucleotide selected from the group consisting of: thymidine, 2'-deoxyadenosine, 2'-deoxycytidine, and 2'-deoxyguanosine.

91. (New) An article according to claim 90, wherein the nucleotide-containing group is attached via a phosphotriester group.

92. (New) An article according to claim 82, wherein substituent C is a nucleotide-containing group including a plurality of nucleotides.


93. (New) An article according to claim 82, wherein substituent C is a nucleotide-containing group.

94. (New) A support for oligonucleotide synthesis comprising: a support material represented by the following formula:



wherein substituent A is a member selected from the group consisting of H, an alkyl group, and an aryl group;

wherein substituent B is the following substituent:




wherein lcaaCPG and its accompanying substituent groups represent a long chain alkylamino controlled pore glass base material; and

wherein substituent C is a member selected from the group consisting of a dimethoxytrityl group and a protecting group removable under acidic or neutral conditions.

95. (New) A support according to claim 94, wherein substituent A is hydrogen.
96. (New) A support according to claim 94, wherein substituent A is an alkyl group.
97. (New) A support according to claim 94, wherein substituent A is a phenyl group.
98. (New) A support according to claim 94, wherein substituent A is a CF₃ group.
99. (New) A support according to claim 94, wherein substituent A is a methyl group.


100. (New) A support according to claim 94, wherein substituent A is a t-butyl group.

101. (New) A support according to claim 94, wherein the support material is




wherein DMTr represents a dimethoxytrityl group.

102. (New) A support according to claim 94, wherein the support material is




wherein DMTr represents a dimethoxytrityl group.

103. (New) A support according to claim 94, wherein the support material is




wherein DMTr represents a dimethoxytrityl group.

104. (New) A support according to claim 94, wherein the support material is




wherein DMTr represents a dimethoxytrityl group.

105. (New) An article represented by the following formula:



wherein substituent A is a member selected from the group consisting of H, an alkyl group, and an aryl group;


wherein substituent B is the following substituent:




wherein lcaaCPG and its accompanying substituent groups represent a long chain alkylamino controlled pore glass base material; and

wherein substituent C is a member selected from the group consisting of a dimethoxytrityl group, a nucleotide-containing group, and a protecting group removable under acidic or neutral conditions.


106. (New) An article according to claim 105, wherein substituent A is hydrogen.
107. (New) An article according to claim 105, wherein substituent A is an alkyl group.
108. (New) An article according to claim 105, wherein substituent A is a phenyl group.
109. (New) An article according to claim 105, wherein substituent A is a CF₃ group.
110. (New) An article according to claim 105, wherein substituent A is a methyl group.
111. (New) An article according to claim 105, wherein substituent A is a t-butyl group.
112. (New) An article according to claim 105, represented by the following formula:




113. (New) An article according to claim 105 represented by the following formula:



114. (New) An article according to claim 105 represented by the following formula:



115. (New) An article according to claim 105 represented by the following formula:



116. (New) An article according to claim 105, wherein substituent C is a nucleotide-containing group including at least one nucleotide selected from the group consisting of: thymidine, 2'-deoxyadenosine, 2'-deoxycytidine, and 2'-deoxyguanosine.

Appln. No.: 09/995,785 (Attorney Docket No. 005416.00004)
Amendment dated January 6, 2004
Reply to Final Office Action of October 7, 2003

been placed in this previously designated "favorable" form, no new issues are raised by this Amendment that would require further searching or consideration by the Examiner. Entry of this Amendment and allowance of claims 74-119 are earnestly solicited.

Applicants believe that no fee is required for this submission. However, if any fees are required, such as fees under 37 C.F.R. §§ 1.16 or 1.17, or if an extension of time is necessary that is not accounted for in the papers filed with this Amendment, the Commissioner is authorized to debit our Deposit Account No. 19-0733 for any necessary fees, including any necessary extension fees.


All rejections having been addressed, Applicants respectfully submit that the instant application is in condition for immediate allowance and respectfully solicits prompt notification of the same.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Dated: January 6, 2004

By:


William F. Rauchholz
Registration No. 34,701

1001 G Street, N.W.
Washington, D.C. 20001-4597
Tel: (202) 824-3000
Fax: (202) 824-3001
WFR/dah